- Conditions
- Magnetic Resonance Imaging Contrast Agents
- Interventions
- Magnevist, Dotarem, Gadovist
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 500 participants
- Timeline
- 1990 – 2019
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 63
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Interventions
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
- Procedure · Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- CNS Lesion, Blood Brain Barrier Defect
- Interventions
- P03277, Gadobenate dimeglumine, MRI
- Drug · Device
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
- Conditions
- Brain Neoplasms
- Interventions
- Whole Brain Irradiation, Partial Brain Irradiation, Neuropsychological Testing, Quality of Life Questionnaire, Magnetic Resonance Imaging (MRI) Assessments
- Radiation · Behavioral · Device
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Sclerosis
- Interventions
- SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more
- Conditions
- Myocardial Infarction
- Interventions
- Magnevist (Gadopentetate dimeglumine, BAY86-4882)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 6
- States / cities
- San Diego, California • Winston-Salem, North Carolina • Tulsa, Oklahoma + 3 more
- Conditions
- Uterine Bleeding, Uterine Fibroids, Adenomyosis
- Interventions
- Evaluation of MRI, US for pelvic and uterine conditions, Patient preference between MRI and Ultrasound
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Artery Disease, Coronary Microvascular Disease
- Interventions
- Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent
- Device · Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neurofibromatosis Type 1, Precancerous Condition
- Interventions
- fludeoxyglucose F 18, gadopentetate dimeglumine
- Radiation
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 2 Months to 23 Months
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 9
- States / cities
- San Diego, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Cardiovascular Injury, Prostate Carcinoma
- Interventions
- Magnetic Resonance Imaging, Exercise Intervention, Perfusion Magnetic Resonance Imaging, Spectroscopy, Laboratory Biomarker Analysis
- Procedure · Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer, Ductal Carcinoma in Situ - Category
- Interventions
- (18F)FES, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Carcinoma
- Interventions
- Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Primary Immunodeficiency
- Interventions
- Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Oligometastatic Disease, Liver Metastases, Colorectal Cancer
- Interventions
- Gadoxetate disodium, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Central Nervous System Diseases
- Interventions
- gadobenate dimeglumine
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Interventions
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
- Conditions
- Coronary Artery Disease
- Interventions
- Coronary MR Angiography (CMRA)
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Plaque Psoriasis.
- Interventions
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Meniere Disease
- Interventions
- Gadopentetate dimeglumine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Renal Insufficiency
- Interventions
- Not listed
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
- Interventions
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24,, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California